Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Osanetant - Novel Investigational Agent for Treatment of Schizophrenia



Affecting around 1% of the general population, schizophrenia is a severe and debilitating mental illness. (Source: ABPI)


Back to Project Details



Related Projects

Erbitux (Cetuximab)
Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for...

Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

Xolair - Biological Therapy
The product of a joint development programme between Tanox, Genentech...

Exanta - Oral Direct Thrombin Inhibitor for the
Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI)...

Prexige - COX-2 Inhibitor
Prexige (lumiracoxib) is an innovative COX-2 inhibitor developed by...

See all projects


Twitter Twitter    Facebook Facebook   
Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2012 Net Resources International, a trading division of SPG Media Limited.